# Dose-ranging Study to Evaluate Efficacy of SLV339 in Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis

> **NCT00630279** · PHASE2 · TERMINATED · sponsor: **Solvay Pharmaceuticals** · enrollment: 56 (actual)

## Conditions studied

- Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Recombinant Microbial Lipase SLV339
- **DRUG:** Recombinant Microbial Lipase SLV339
- **DRUG:** Recombinant Microbial Lipase SLV339

## Key facts

- **NCT ID:** NCT00630279
- **Lead sponsor:** Solvay Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 56 (ACTUAL)
- **Why stopped:** This trial discontinued March 7,2009 due to high screen failure rate.
- **Last updated:** 2009-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00630279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00630279, "Dose-ranging Study to Evaluate Efficacy of SLV339 in Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00630279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*